AdipoGen Life Sciences COVID-19 antiviral research compounds
There are no approved drugs to treat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19). Existing drugs, which have a known favourable safety profile, are being examined for strategies to treat the disease and fast-track a treatment plan. Several influenza and HIV drugs are currently undergoing clinical trial in coronavirus patients. The rational selection of drugs already on the market is being made based on their ability to inhibit any proteins essential for virus-receptor interaction and/or viral life cycle.
AdipoGen Life Sciences’ range of Small Molecule SARS-CoV-2 Inhibitors and Modulators offers potential tools for in vitro studies of COVID-19. The company’s product range includes research compounds targeting viral transcription, replication and maturation.
Phone: 02 9698 2022
Beckman Coulter Life Sciences IR820 and IR870 infrared dye antibody conjugates
The products provide research flow cytometry labs with a low-noise solution, including single...
AdipoGen Life Sciences PANoptosis research antibodies
AdipoGen Life Sciences provides thoroughly validated and published antibodies for PANoptosis,...
Cytek 16-Color NK Cell Immunoprofiling Panel
The Cytek 16-Color NK Cell Immunoprofiling Panel is designed and optimised by Cytek scientists to...
